On the other hand, detecting myositis-specific antibodies (anti-Mi-2, anti-SRP, anti-synthetase Ab) and myositis-associated antibodies (anti-RNP, anti-Ku, anti-PM-Slc) is associated with a decreased risk of malignancy and an increased risk of interstitial lung disease [139]. Here, CCL21 is linked to myositis disease.